STRIDE-III says not every missed IBD target warrants a treatment change

Share

Updated international recommendations for managing inflammatory bowel disease, published in The Lancet Gastroenterology & Hepatology, distinguish between treatment targets that should generally prompt a change in therapy after treatment is optimized and those that call for optimization and closer monitoring. They also set a fecal calprotectin target of less than 200 μg/g for both Crohn’s disease (CD) and ulcerative colitis (UC), define treatment-specific times to reach targets, and create a separate patient-centered pathway for fatigue, disability, and quality of life.

Known as STRIDE-III, for Selecting Therapeutic Targets in Inflammatory Bowel Disease, the recommendations were developed by the International Organization for the Study of Inflammatory Bowel Disease (IOIBD).

“For me, the central message is that controlling inflammation and improving patients’ lives are both essential,” one of the review’s authors, Virginia Solitano, MD, of the IRCCS San Raffaele Scientific Institute, Milan, Italy, told GI & Hepatology News. “Persistent fatigue or impaired quality of life deserves attention even when inflammatory targets have been achieved. Successful care requires us to ask both whether the disease is controlled and whether the patient is doing well.”

Dr. Solitano, first author Dan Turner, MD, of Shaare Zedek Medical Center, Jerusalem, and colleagues updated the 2021 STRIDE-II recommendations based on systematic literature reviews, expert surveys, and modified Delphi consensus voting.

The researchers reviewed publications from July 1, 2019, through April 18, 2025, screening 13,071 records and including 1,018 studies: 462 on CD, 335 on UC, and 221 on both conditions. Surveys were completed by 60 of 79 international gastroenterologists and 23 of 30 pediatric gastroenterologists. Sixty IOIBD members then voted; consensus required at least 75% of participants to rate a statement 7 to 10 on a 10-point scale.

Three categories of treatment targets

STRIDE-III divides treatment targets into three categories: actionable, adjunctive, and patient-centered.

Actionable targets include symptom improvement, clinical remission, normalization of C-reactive protein (CRP), fecal calprotectin within the target range, and endoscopic remission. These targets are supported by treat-to-target trials or, for symptom-based outcomes, were designated as patient priorities. Failure to achieve them generally warrants a treatment change after efforts to optimize therapy, according to the recommendations.

Adjunctive targets, including bowel urgency, histologic remission in UC, transmural remission in CD, and normal growth in children, are supported by observational associations but lack trials showing a benefit over established actionable targets. They can guide treatment adjustments and monitoring without necessarily requiring a change in therapy.

Bowel urgency is new to STRIDE-III. “Although it is highly relevant to patients and should be systematically assessed, persistent urgency alone does not automatically justify treatment escalation,” Dr. Solitano commented. “Instead, it should prompt evaluation of residual inflammation and potential noninflammatory contributors, with treatment decisions guided by the overall clinical context.”

Patient-centered targets include disability, quality of life, and, newly added, fatigue. According to the recommendations, persistent problems should prompt assessment of inflammation and other possible causes, followed by shared decisions about next steps.

According to the authors, requiring interventional evidence helps balance therapeutic ambition against adverse effects, treatment burden, and cost, because associations between deeper remission and favorable outcomes do not necessarily establish that further treatment escalation will improve outcomes.

Updated biomarker thresholds

The fecal calprotectin target of less than 200 μg/g applies to both CD and UC. Values below 100 μg/g are associated with deeper disease control, and the authors said levels between 100 and 200 μg/g should be interpreted based on each patient’s condition. For UC, IOIBD members scored 150 and 200 μg/g almost identically, and the steering committee chose 200 μg/g, calling it relatively conservative.

According to STRIDE-III, levels that remain above 200 μg/g despite adequate treatment should prompt reassessment. The authors emphasized the importance of repeat testing because levels can vary and may be affected by infections, medications, and other conditions.

The recommended CRP target is less than 5 mg/L. Mildly elevated CRP, less than twice the upper limit of normal, should be interpreted individually, according to the authors.

Treatment timeline

STRIDE-III identifies four stages for assessing treatment, with targets that change as patients respond.

In the immediate stage, generally within one to two months, the focus is on improving symptoms. The short-term stage, within two to three months, aims for clinical remission and early improvement in inflammatory markers. The authors said a decrease of at least 50% in fecal calprotectin or CRP levels from baseline is expected at this stage and may represent a meaningful response even if the absolute target has not been reached.

During the intermediate stage, at four to six months, the aim is to bring inflammatory markers into the recommended ranges.

The long-term stage, at seven to 12 months, focuses on achieving endoscopic remission. For CD, this means a Simple Endoscopic Score for Crohn’s Disease of 2 or less. For UC, the preferred target is a Mayo endoscopic score of 0.

The authors emphasized that these timelines are flexible and depend on the treatment used. Their rough estimates for clinical remission were four to 12 weeks for antitumor necrosis factor therapy and 12 to 18 weeks for thiopurines. They said continuing treatment with close monitoring may be appropriate, following shared decision-making, for some patients who have little remaining inflammation and otherwise good disease control. The recommendations also adapt monitoring for resource-limited settings.

Deeper remission

Histologic remission in UC and transmural remission in CD are now adjunctive long-term targets. Although both are linked to better outcomes, there is not enough evidence to recommend changing therapy solely because patients have not achieved them, the authors said. The recommendations do not designate histologic remission in CD or transmural remission in UC as targets.

Limitations

Limitations include varying levels of evidence supporting the targets, a limited number of clinical trials, and reliance on indirect evidence for some recommendations, which the authors said applies mostly to UC biomarker targets. STRIDE-III applies to medically managed luminal disease and should not be extrapolated directly to perianal disease, pouchitis, extraintestinal manifestations, or postoperative management. The authors called thresholds and timelines pragmatic clinical guidance rather than absolute biological cutoffs.

The authors wrote that STRIDE-III should be interpreted as “a pragmatic framework of treatment principles rather than a rigid algorithm in which crossing a single numerical threshold automatically determines treatment change.”

The initiative was supported by IOIBD. Dr. Solitano reported fees or travel grants from Johnson & Johnson, Celltrion, Pfizer, Takeda, Giuliani, Tillotts, Alfasigma, Lilly, and AbbVie. Dr. Turner and 20 other authors reported financial relationships with industry; five reported none.

Virginia Solitano, MD

Expert insight

Dr. Solitano shared her perspective on the recommendations.

What are the most important changes in STRIDE-III, and how should they affect treatment decisions?

Dr. Solitano: The key advance is a clearer distinction between targets that should drive treatment changes and those that guide optimization and monitoring. Actionable targets include clinical response and remission, normalization of C-reactive protein, fecal calprotectin within the target range, and endoscopic remission. Adjunctive targets, including histologic remission in ulcerative colitis and transmural remission in Crohn’s disease, inform management but do not automatically require switching therapeutic class. STRIDE-III also gives fatigue, disability, and quality of life a distinct patient-centered pathway and introduces treatment-specific timelines.

How should clinicians use symptoms, biomarkers, and endoscopic findings?

Dr. Solitano: These measures provide complementary information. Symptoms tell us how patients feel, biomarkers help track inflammation between procedures, and endoscopy assesses mucosal disease activity. They should be interpreted together and over time, allowing for the expected response to the treatment being used.

In practice, discordant results deserve investigation. Persistent symptoms should not automatically lead to escalation without assessing whether inflammation is responsible. Similarly, feeling well should not be taken as proof that inflammation has resolved.

What are the biggest challenges to implementation, particularly when patients feel well?

Dr. Solitano: One major challenge is explaining why further assessment or treatment adjustment may be appropriate when a patient feels well. That conversation should acknowledge the patient’s experience while explaining what the objective findings mean for their individual disease.

Access to testing, costs, and the burden of repeated monitoring are also practical barriers. My approach would be to agree on the goals and monitoring plan early, then discuss any proposed adjustment in terms of its expected benefits, risks, and the patient’s preferences. An isolated abnormal result needs clinical interpretation before a treatment decision